Fangyuan Capital

Fangyuan Capital is a private equity investment firm based in Hong Kong, China, that focuses on allocating capital across the life sciences, healthcare, and related medical technology sectors. The organization operates as an institutional investment manager overseeing a diverse vehicle portfolio that currently includes two United States dollar funds, one renminbi fund, and several targeted single project funds. Operating as a licensed entity under the regional Securities and Futures Commission, its specific Fangyuan Capital SPC structure is financially backed by twenty distinct limited partners. The firm targets emerging entrepreneurial teams to provide comprehensive financial support from the early startup development phases through to initial public offerings, backing notable portfolio companies such as Jacobio Pharmaceuticals, XtalPi, Innorna, LePure, and Bluepha. Fangyuan Capital was officially founded in 2018 by an undisclosed group of original founding partners.